Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PIRS Pieris: Shares Can Still Soar Much Higher, Says Analyst
https://finance.yahoo.com/news/pieris-shares-still-soar-much-223725498.html
Yup buy signal about to come in$$$
Higher lows is what we are looking for. We will see where we are end of day
This pos is trading like pinksheet junk imo
Volume is slowing down. May see some consolidation for a few days
* * $PIRS Video Chart 05-27-2021 * *
Link to Video - click here to watch the technical chart video
Agree inpatient sellers why sell for copper when gold is near
Yup
Biggest difference is we still have a good amount of sellers. Fools
Much like Tuesdays trading but at higher levels. As healthy as it gets
Pieris: Shares Can Still Soar Much Higher, Says Analyst
Source: TipRanks
There’s nothing like a slice of good news to send the stock of a micro-cap biotech on an almighty tear. On Tuesday, the blueprint was followed to a tee. Shares of Pieris Pharmaceuticals (PIRS) more than doubled in the session after it was announced that the Boston-based company had nabbed a deal that could generate it a lot of money. Specifically, the company said it was forming a partnership with Roche subsidiary Genentech to collaborate on the development of respiratory and ophthalmology therapies based on Pieris' Anticalin technology. Pieris will secure an upfront payment of $20 million and will be entitled to over $1.
https://www.tipranks.com/news/article/pieris-shares-can-still-soar-much-higher-says-analyst
Rezolute, Syros Pharmaceuticals leads healthcare gainers; NextGen Healthcare, Protagenic Therapeutics among major losers
May 27, 2021 11:06 AM ETLantheus Holdings, Inc. (LNTH), Organogenesis Holdings Inc. (ORGO), Pieris Pharmaceuticals, Inc. (PIRS)...By: Khyathi Dalal, SA News Editor
Gainers: Rezolute (NASDAQ:RZLT) +44%, Syros Pharmaceuticals (NASDAQ:SYRS) +19%, Lantheus (NASDAQ:LNTH) +17%, Pieris Pharmaceuticals (NASDAQ:PIRS) +14%, Organogenesis (NASDAQ:ORGO) +10%.
As this moves more volume will come in and we will skyrocket. Obviously isn't ihub money here. Especially when HCW is backing it up with a $9 price target
Yes! $$$$$$$$$$$$$$$$$$%$$$
That would be awesome let’s do it $$$
6 today?
Soon the $4's. $$$$$$$$$$$$$$$$
Loading Zone $$$$
That is interesting. Very. Manipulation at its finest
Hmmm... Very interesting timing for that HCW Analyst to 'Release' his 'research' on price prospects for PIRS PPS AH at 5:37 PM today! It is as if some Hedge Fund Clients of HCW pushed their MMs to pummel the PPS so that They could put on a BIG LONG position today. I would not be surprised IF they bought up MM Share initial positions in PIRS today!
Or the $5s, $4s, $3s, $2s, or $1s
They worked all day drilling it down. Looks like they’re satisfied for now in the 3.40’s hopefully they get want they want and unleash it
* * $PIRS Video Chart 05-26-2021 * *
Link to Video - click here to watch the technical chart video
Damn! It’s getting drilled. Shorty’s gotta cover. It’ll rise again.
Those wicks are looking better. Looks like the buying pressure is starting to tick up
Those bearish wicks are a little concerning.
still confident though
Rebuying if it holds $3.50 today.
Pieris Pharma jumps on collaboration with Genentech
May 25, 2021 9:02 Pieris Pharmaceuticals, Inc. (PIRS)
By: Dulan Lokuwithana, SA News Editor8 Comments
Pieris Pharmaceuticals (NASDAQ:PIRS) has gained ~25.9% in the pre-market after announcing a multi-program research collaboration and license agreement with Genentech, a subsidiary of Roche Holding (OTCQX:RHHBY).
The agreement will allow Pieris to combine its proprietary drug discovery with Genentech's to target treatments for respiratory and ophthalmological diseases.
“This collaboration further expands our partnered efforts in respiratory diseases and opens a new avenue for our Anticalin technology to potentially provide patient benefit through local biological effects,” commented Stephen S. Yoder CEO of Pieris.
Per the terms of the deal, Pieris will be entitled to an upfront payment of $20M and milestone payments of more than $1.4B across several programs. That is in addition to tiered royalties for commercialized programs.
Pieris will run research and early preclinical development of the programs and Genentech will take over the IND-enabling activities, clinical development, and commercialization of those programs. In return for an option exercise fee, Genentech will also have the option to select additional targets.
In April, a licensing agreement with Boston Pharmaceuticals enabled Peiris to receive an upfront payment of $10M and up to $353M in milestone payments.
Eyes glued around 3.76
Gap 3.76 then run
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
528
|
Created
|
06/26/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |